1-CBZ-2-羟甲基吲哚啉 | 135829-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-CBZ-2-羟甲基吲哚啉
• 中文别名: 2,3-二氢-2-(羟甲基)-1H-吲哚-1-羧酸苄酯；2-(羟基甲基)吲哚啉-1-羧酸苄酯
• 英文名称: benzyl 2-(Hydroxymethyl)-1-indolinecarboxylate
• 英文别名: 1-Benzyloxycarbonylindoline-2-methanol；1-benzyloxycarbonyl-2-hydroxymethylindoline；benzyl 2-(hydroxymethyl)-2,3-dihydroindole-1-carboxylate
• CAS: 135829-04-8
• 化学式: C₁₇H₁₇NO₃
• mdl: MFCD02682013
• 分子量: 283.327
• InChiKey: QSMOQTIGILELKY-UHFFFAOYSA-N

物化性质

• 熔点：
  67 °C
• 密度：
  1.251±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.235
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Name:	Benzyl 2-(hydroxymethyl)-1-indolinecarboxylate 95+% Material Safety Data Sheet
Synonym:	2-Hydroxymethyl-2,3-dihydro-indole-1-carboxylic acid benzyl este
CAS:	135829-04-8

Section 1 - Chemical Product MSDS Name:Benzyl 2-(hydroxymethyl)-1-indolinecarboxylate 95+% Material Safety Data Sheet
Synonym:2-Hydroxymethyl-2,3-dihydro-indole-1-carboxylic acid benzyl este

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
135829-04-8	Benzyl 2-(hydroxymethyl)-1-indolinecar	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 135829-04-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: pleasant odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 60 - 62 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H17NO3
Molecular Weight: 283.33

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 135829-04-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzyl 2-(hydroxymethyl)-1-indolinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 135829-04-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 135829-04-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 135829-04-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-CBZ-2-羟甲基吲哚啉 在 acid phosphatase 、 fuculose-1-phosphate aldolase variant F₁₃₁A 、 2-碘酰基苯甲酸 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成
  参考文献：
  名称：

  Aldolase-Catalyzed Synthesis of Conformationally Constrained Iminocyclitols: Preparation of Polyhydroxylated Benzopyrrolizidines and Cyclohexapyrrolizidines

  摘要：

  A straightforward chemo-enzymatic synthesis of new polyhydroxylated benzopyrrolizidines and cyclohexapyrrolizidines is developed. The two-step strategy consists of L-fuculose-1-phosphate aldolase variant F131A-catalyzed aldol addition of dihydroxyacetone phosphate to rac-N-benzyl-oxycarbonyfindoline-2-carbaldehyde as well as (2S*,3aS*,7aS*)- and (2S*,3aR*,7aR*)-N-benzyloxycarbonyloctahydroindole-2-carbaldehydes and a subsequent one-step catalytic deprotection-reductive amination.

  DOI：

  10.1021/ol5002158
• 作为产物：
  描述：

  吲哚啉-2-羧酸 在 sodium tetrahydroborate 、 氯化亚砜 、 N,N-二异丙基乙胺 、 calcium chloride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 50.0h， 生成 1-CBZ-2-羟甲基吲哚啉
  参考文献：
  名称：

  Aldolase-Catalyzed Synthesis of Conformationally Constrained Iminocyclitols: Preparation of Polyhydroxylated Benzopyrrolizidines and Cyclohexapyrrolizidines

  摘要：

  A straightforward chemo-enzymatic synthesis of new polyhydroxylated benzopyrrolizidines and cyclohexapyrrolizidines is developed. The two-step strategy consists of L-fuculose-1-phosphate aldolase variant F131A-catalyzed aldol addition of dihydroxyacetone phosphate to rac-N-benzyl-oxycarbonyfindoline-2-carbaldehyde as well as (2S*,3aS*,7aS*)- and (2S*,3aR*,7aR*)-N-benzyloxycarbonyloctahydroindole-2-carbaldehydes and a subsequent one-step catalytic deprotection-reductive amination.

  DOI：

  10.1021/ol5002158

文献信息

• Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040054173A1

  公开（公告）日：2004-03-18

  Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1 A′ is pyrrole; R 1′ is phenyl or naphthyl; R 2′ is pyridyl or pyrimidinyl; R 3′ is (IIa)′, (IIb)′ or (IIc)′: 2 m′ is 1; E′ is nitrogen; D′ is >C(R 5′ )—, R 5′ is hydrogen, Substituent &agr;′ or Substituent &bgr;′; B′ is nitrogen-containing 5-membered heterocyclic; R 4′ is 1 to 3 substituents from Substituent &agr;′, Substituent &bgr;′ and Substituent &ggr;′; R 1′ and R 3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R 2′ ; Substituent &agr;′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NR a′ R b′ ; R a′ and R b′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or R a′ and R b′ with the nitrogen atom form a heterocyclyl; Substituent &bgr;′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent &ggr;′ is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.

  具有对抗公式(I)′炎症细胞因子生成活性的化合物： 1 A′是吡咯；R 1′ 是苯基或萘基；R 2′ 是吡啶基或嘧啶基；R 3′ 是(IIa)′，(IIb)′或(IIc)′： 2 m′是1；E′是氮；D′是>C(R 5′ )—, R 5′ 是氢，取代基α′或取代基β′；B′是含氮的5-成员杂环；R 4′ 是来自取代基α′，取代基β′和取代基γ′的1至3个取代基；R 1′ 和R 3′ 分别与吡咯环上与R 2′ 相连的吡咯原子的两个相邻原子成键；取代基α′是羟基，硝基，氰基，卤素，烷氧基，卤代烷氧基，烷基亚砜，卤代烷基亚砜或—NR a′ R b′ ；R a′ 和R b′ 是氢，烷基，烯基，炔基，芳烷基或烷基亚磺酰基，或者R a′ 和R b′ 与氮原子形成杂环；取代基β′是烷基，烯基，炔基，芳烷基或环烷基；取代基γ′是氧代，羟基亚胺，烷氧基亚胺，亚烷基，亚烷基二氧，烷基亚磺酰基，烷基亚磺酰基，芳基，芳氧基，亚烷基或芳亚烷基。
• Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
  申请人：The Upjohn Company

  公开号：US05231188A1

  公开（公告）日：1993-07-27

  The present invention involves tricyclic-fused 6-member ring oxazolidinones ##STR1## and tricyclic-fused 5-member ring oxazolidinones ##STR2## which are useful as antibacterial agents.

  这项发明涉及三环融合的6-成员环噁唑烷酮和三环融合的5-成员环噁唑烷酮，它们可用作抗菌剂。
• Heterocycle carboxamides as antiviral agents
  申请人：——

  公开号：US20020025959A1

  公开（公告）日：2002-02-28

  The present invention provides a compound of formula I 1 which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

  本发明提供了一种化合物，其化学式为I1，可作为抗病毒药物，特别是用作抗疱疹病毒家族的药物。
• Tricyclic [6,6,5]-fused oxazolidinone antibacterial agents
  申请人：The Upjohn Company

  公开号：US05247090A1

  公开（公告）日：1993-09-21

  The present invention involves tricyclic-fused 6-member ring oxazolidinones ##STR1## which are useful as antibacterial agents.

  本发明涉及三环融合的6元环噁唑烷酮##STR1##，其作为抗菌剂具有用途。
• Bicyclic unsaturated tertiary amine compounds
  申请人：Kimura Tomio

  公开号：US20050159444A1

  公开（公告）日：2005-07-21

  A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I): wherein A represents pyrrole or pyrazole, R 1 represents an aryl group or a heteroaryl group which may be substituted, R 2 represents a heteroaryl group which may be substituted, and R 3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.

  一种双环不饱和三级胺化合物，能够抑制炎症细胞因子的产生。该化合物的化学式如下（I）：其中A代表吡咯或吡唑，R1代表取代的芳基或杂环基，R2代表取代的杂环基，R3代表吲哚啉基，或其药学上可接受的盐、酯或衍生物。